Prosecution Insights
Last updated: May 29, 2026

National University Corporation Tokyo Medical And Dental University

10 pending office actions • 9 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

10
Total Pending OAs
7
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
1
Due this week
3
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 7 days (1)Due ≤ 30 days (3)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
7
Medium (70%)
0
Easy (0%)
3
Unknown (30%)

Rejection Statute Mix

BucketCases
§103 only6 (60%)
§102 only1 (10%)
No statute on record3 (30%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
70% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
3
Mechanical / Eng
30% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

100 h
Manual time on pending OAs
20 h
Time saved (low, 20%)
35 h
Time saved (mid, 35%)
0.9 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HUDSON, AMY ROSE 2 75.1% +11.4%
CARREIRO, CAITLIN ANN 1 45.5% +40.3%
BECCIA, CHRISTOPHER J 1 83.4% +14.0%
AEDER, SEAN E 1 56.9% +19.6%
SHIAO, YIH-HORNG 1 72.6% +75.6%
PARK, EVELYN GRACE 1 54.2% +45.8%
KENYON, JOHN S 1 80.3% +17.4%
KIM, TAEYOON 1 51.5% +51.4%
D' AMBROSIO, THEA 1 55.6% +56.8%

Quick Wins (2)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18113369 DIAGNOSIS METHODS, DIAGNOSTIC AGENTS, AND THERAPEUTIC AGENTS AGAINST ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION, AND SCREENING METHODS FOR THESE AGENTS KENYON, JOHN S 19d
18780198 GUIDE DEVICE BECCIA, CHRISTOPHER J 62d

Interview Candidates (10)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17602035 Pharmaceutical Composition for Treating Muscle Disease HUDSON, AMY ROSE 79d overdue
17906444 HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID HUDSON, AMY ROSE 43d overdue
18146109 PRODUCTION METHOD FOR SYNOVIUM-DERIVED MESENCHYMAL STEM CELLS AND PRODUCTION METHOD FOR CELL PREPARATION FOR JOINT MEDICAL TREATMENT KIM, TAEYOON 37d overdue
17631934 AGENT FOR PREVENTING OR TREATING MILD COGNITIVE IMPAIRMENT D' AMBROSIO, THEA 5d overdue
19108416 ORAL USE OF AN IN-MOUTH WEARABLE DEVICE IN THE TREATMENT OF DYSPHAGIA CARREIRO, CAITLIN ANN 3d overdue
18256222 Agent for Preventing or Treating Frontotemporal Lobar Degeneration AEDER, SEAN E 5d
18128561 INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND NON-TRANSITORY COMPUTER READABLE MEDIUM PARK, EVELYN GRACE 12d
18113369 DIAGNOSIS METHODS, DIAGNOSTIC AGENTS, AND THERAPEUTIC AGENTS AGAINST ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION, AND SCREENING METHODS FOR THESE AGENTS KENYON, JOHN S 19d

Top Art Units

Art UnitApps
1636 2
3786 1
3775 1
1642 1
1691 1
3791 1
1625 1
1631 1
1654 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19108416 ORAL USE OF AN IN-MOUTH WEARABLE DEVICE IN THE TREATMENT OF DYSPHAGIA CARREIRO, CAITLIN ANN 3786 §103 Non-Final OA 3d overdue Pending Mar 03, 2025
18780198 GUIDE DEVICE BECCIA, CHRISTOPHER J 3775 §103 Non-Final OA 62d Pending Jul 22, 2024
18256222 Agent for Preventing or Treating Frontotemporal Lobar Degeneration AEDER, SEAN E 1642 Other Non-Final OA 5d Pending Jun 07, 2023
18254488 POLYROTAXANE HAVING HYDROXY GROUP OR SULFO GROUP SHIAO, YIH-HORNG 1691 §102 Non-Final OA 22d Pending May 25, 2023
18128561 INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND NON-TRANSITORY COMPUTER READABLE MEDIUM PARK, EVELYN GRACE 3791 §103 Final Rejection 12d Pending Mar 30, 2023
18113369 DIAGNOSIS METHODS, DIAGNOSTIC AGENTS, AND THERAPEUTIC AGENTS AGAINST ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION, AND SCREENING METHODS FOR THESE AGENTS KENYON, JOHN S 1625 §103 Non-Final OA 19d Pending Feb 23, 2023
18146109 PRODUCTION METHOD FOR SYNOVIUM-DERIVED MESENCHYMAL STEM CELLS AND PRODUCTION METHOD FOR CELL PREPARATION FOR JOINT MEDICAL TREATMENT KIM, TAEYOON 1631 Other Final Rejection 37d overdue Pending Dec 23, 2022
17906444 HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID HUDSON, AMY ROSE 1636 Other Non-Final OA 43d overdue Pending Sep 15, 2022
17631934 AGENT FOR PREVENTING OR TREATING MILD COGNITIVE IMPAIRMENT D' AMBROSIO, THEA 1654 §103 Non-Final OA 5d overdue Pending Jun 07, 2022
17602035 Pharmaceutical Composition for Treating Muscle Disease HUDSON, AMY ROSE 1636 §103 Final Rejection 79d overdue Pending Oct 07, 2021

Managing National University Corporation Tokyo Medical And Dental University's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month